■由于免疫系统受损,COVID-19大流行增加了血液系统恶性肿瘤患者的风险,导致更严重的结局和死亡率增加。虽然像疫苗这样的干预措施,靶向抗病毒药物,单克隆抗体对普通人群有效,他们对这些患者的益处可能没有那么明显。
■EPICOVIDEHA注册(国家临床试验标识符,NCT04733729)收集了自全球大流行以来的血液恶性肿瘤患者的COVID-19数据。它遍布全球各地,允许在前三年(2020-2022年)进行全面分析。
■EPICOVIDEHA注册中心收集了2020年1月至2022年12月的数据,涉及来自41个国家/地区152个中心的8767例血液恶性肿瘤患者的COVID-19病例。42%是女性。在此期间,危重感染显著减少,死亡率总体从29%下降至4%.然而,住院治疗,特别是在ICU,仍然与较高的死亡率有关。导致死亡率增加的因素包括年龄,多种合并症,COVID-19发作时的活动性恶性肿瘤,肺部症状,和住院。积极的一面,接种一到两剂或三剂或更多剂量的疫苗,以及在2022年遇到COVID-19,与生存率提高有关。
■血液系统恶性肿瘤患者仍面临高风险,尽管随着时间的推移,严重感染和总死亡率有所下降。住院治疗,尤其是在ICU,仍然是一个重大关切。该研究强调了疫苗接种的重要性和2022年COVID-19暴露的时机,以提高该患者组的生存率。持续的监测和有针对性的干预措施对于支持这一弱势群体至关重要,强调及时诊断和及时治疗在预防严重COVID-19病例中的关键作用。
■不适用。
UNASSIGNED: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.
UNASSIGNED: The EPICOVIDEHA registry (National Clinical Trials Identifier, NCT04733729) gathers COVID-19 data from hematological malignancy patients since the pandemic\'s start worldwide. It spans various global locations, allowing comprehensive analysis over the first three years (2020-2022).
UNASSIGNED: The EPICOVIDEHA registry collected data from January 2020 to December 2022, involving 8767 COVID-19 cases in hematological malignancy patients from 152 centers across 41 countries, with 42% being female. Over this period, there was a significant reduction in critical infections and an overall decrease in mortality from 29% to 4%. However, hospitalization, particularly in the ICU, remained associated with higher mortality rates. Factors contributing to increased mortality included age, multiple comorbidities, active malignancy at COVID-19 onset, pulmonary symptoms, and hospitalization. On the positive side, vaccination with one to two doses or three or more doses, as well as encountering COVID-19 in 2022, were associated with improved survival.
UNASSIGNED: Patients with hematological malignancies still face elevated risks, despite reductions in critical infections and overall mortality rates over time. Hospitalization, especially in ICUs, remains a significant concern. The study underscores the importance of vaccination and the timing of COVID-19 exposure in 2022 for enhanced survival in this patient group. Ongoing monitoring and targeted interventions are essential to support this vulnerable population, emphasizing the critical role of timely diagnosis and prompt treatment in preventing severe COVID-19 cases.
UNASSIGNED: Not applicable.